Eli Lilly's next-generation obesity drug retatrutide has cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c by an average of 1.7% to 2% across different doses at 40 weeks compared to placebo, meeting the study's main goal. Patients started with an A1C in the range of 7% to 9.5%, and were not taking other diabetes medications. The highest dose of the drug helped patients lose 15.3% of their weight, or 36.6 pounds. Despite these results, the company has yet to file for approval for obesity or diabetes.